Journal Article

DKFZ-2026-02669

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.

Bockstiegel, T. ; Webb, A. ; Aguado-Barrera, M. E. ; Aguado-Flor, E. ; Altabas, M. ; Aznar, M. ; Azria, D. ; Briers, E. ; Bultijnck, R. ; Chang-Claude, J.DKFZ* ; Cicchetti, A. ; De Santis, M. C. ; Dunning, A. ; Fachal, L. ; Fuentes-Rios, O. ; Giraldo, A. ; Gómez-Caamaño, A. ; Gutiérrez-Enríquez, S. ; Herskind, C. ; Heumann, P.DKFZ* ; Johnson, K. ; Kaaks, R.DKFZ* ; Kerns, S. L. ; Lambrecht, M. ; La Rocca, E. ; Mollà, M. ; Rancati, T. ; Reyes, V. M. ; Romero, J. C. R.DKFZ* ; Rosenstein, B. S. ; De Ruysscher, D. ; Seibold, P.DKFZ* ; Shearer, R. M. ; Stobart, H. ; Symonds, R. P. ; Taboada-Valladares, B. ; Talbot, C. J. ; Vega, A. ; Veldeman, L. ; Veldwijk, M. R. ; Ward, T. ; West, C. M. L. ; consortia, R. (Collaboration Author) ; Rattay, T. ; Sperk, E.

2026
Elsevier Amsterdam

Abstract: The international REQUITE study and its follow-up studies (RADprecise/REQUITEplus) prospectively collected longitudinal data from patients undergoing radiotherapy for breast, prostate, or lung cancer. We present data from 2057 women with breast cancer, describing patient-reported outcomes and acute and late adverse effects.Patients were recruited between April 2014 and October 2016. Eligible patients received external-beam photon radiotherapy after breast-conserving surgery, had no metastasis at inclusion, no other malignancy within the previous five years, and no prior breast irradiation. Blood samples were collected before radiotherapy for genotyping, molecular analysis, and biobanking. Standardised assessments included CTCAE v4, EORTC QLQ-C30 and BR23, MFI, GPAQ, and DICOM/DVH data. Follow-up continued annually for two years, extending to eight years at eligible sites.Acute side effects peaked at end of radiotherapy, with erythema in 83-89% of patients. Grade ≥ 2 acute effects, including pain (11% versus 4.3%) and skin ulceration (4.8% versus 0.8%), were more frequent with normofractionation than hypofractionation. Grade ≥ 2 late effects affected between 0.6% and 16.8% of patients; skin induration was the most frequent late effect. Patient-reported outcome scores varied over time, with functional scale scores at two years similar to or higher than at baseline.REQUITE provides real-world evidence of acute and late outcomes following normo- and hypofractionation, broadly consistent with published randomised trials. The dataset, combining clinical adverse effects, quality of life, dosimetric, and genetic data, is a resource for personalised radiotherapy research (www.requite.eu).

Keyword(s): Adverse events ; Breast cancer ; Fractionation ; Patient-reported outcomes ; Prospective cohort study ; REQUITE ; Radiotherapy

---

Contributing Institute(s):

1. Epidemiologie von Krebs (C020)
2. Personalisierte Früherkennung des Prostatakarzinoms (C130)
3. Erimitus im DKFZ (Z999)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2026

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---